SEC 13F Intelligence

Managers / Q1 2022 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$157M
Q1 2022
Positions
86
Filings on Record
30
2019–present window
Filed
May 16, 2022
original filing

Summary

Highvista Strategies LLC reported $157M in U.S.-listed holdings across 86 positions for Q1 2022.

Its largest position, DELL, represents 11.3% of the portfolio.

Compared with Q4 2021, the fund opened 39 new positions and exited 22.

Portfolio Metrics

Turnover
+37.4%
vs prior filed quarter
Top-10 Concentration
+45.1%
share of reported value
Largest Position
+11.3%
Dell Technologies
New / Exited
39 / 22
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 86.1%Other: 11.0%ADR: 2.1%ETP: 0.7%
  • Common Stock · 86.1% · $135M
  • Other · 11.0% · $17M
  • ADR · 2.1% · $3M
  • ETP · 0.7% · $1M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
VVISA INCNEW+41.1K41.1K+$9M$9M
MAMASTERCARD INCORPORATEDNEW+24.2K24.2K+$9M$9M
FISVFISERV INCNEW+83.3K83.3K+$8M$8M
PYPLPAYPAL HLDGS INCNEW+50.7K50.7K+$6M$6M
FISFIDELITY NATL INFORMATION SVNEW+38.3K38.3K+$4M$4M
CERNCHFCERNER CORPNEW+37.3K37.3K+$3M$3M
ATVIEURACTIVISION BLIZZARD INCNEW+40.0K40.0K+$3M$3M
FT2FIRST HORIZON CORPORATIONNEW+135.4K135.4K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DELLDELL TECHNOLOGIES INChistory →CL C11.34%$18M355.4K
2VVISA INChistory →COM CL A5.80%$9M41.1K
3MAMASTERCARD INCORPORATEDhistory →CL A5.50%$9M24.2K
4FISVFISERV INChistory →COM5.37%$8M83.3K
5PYPLPAYPAL HLDGS INChistory →COM3.73%$6M50.7K
6MSD ACQUISITION CORPUNIT 03/25/20263.14%$5M500.0K
7CPNGCOUPANG INChistory →CL A2.88%$5M256.3K
8PBCTEURPEOPLES UNITED FINANCIAL INChistory →COM2.49%$4M196.1K
9FISFIDELITY NATL INFORMATION SVhistory →COM2.45%$4M38.3K
10COHREURCOHERENT INChistory →COM2.36%$4M13.6K
11CHNGUSDCHANGE HEALTHCARE INChistory →COM2.25%$4M162.1K
12CERNCHFCERNER CORPhistory →COM2.22%$3M37.3K
13ATVIEURACTIVISION BLIZZARD INChistory →COM2.04%$3M40.0K
14FT2FIRST HORIZON CORPORATIONhistory →COM2.02%$3M135.4K
15CTXSEURCITRIX SYS INChistory →COM2.01%$3M31.4K
16ACRSACLARIS THERAPEUTICS INChistory →COM1.73%$3M158.2K
17FATEFATE THERAPEUTICS INChistory →COM1.59%$3M64.7K
18CYTKCYTOKINETICS INChistory →COM NEW1.54%$2M65.8K
19KURAKURA ONCOLOGY INChistory →COM1.51%$2M147.8K
20PTGXPROTAGONIST THERAPEUTICS INChistory →COM1.39%$2M92.0K
21RLAYRELAY THERAPEUTICS INChistory →COM1.31%$2M68.6K
22RPTXREPARE THERAPEUTICS INChistory →COM1.30%$2M143.4K
23CATALYST PARTNRS ACQUISITN CUNIT 99/99/99991.28%$2M200.0K
24APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM1.19%$2M36.9K
25GBTUSDGLOBAL BLOOD THERAPEUTICS INhistory →COM1.13%$2M51.1K
26DYNDYNE THERAPEUTICS INChistory →COM1.03%$2M168.7K
27RCUSARCUS BIOSCIENCES INChistory →COM1.00%$2M50.0K
28AMARIN CORP PLCSPONS ADR NEW1.00%$2M476.7K
29BIOHAVEN PHARMACTL HLDG CO LCOM0.96%$2M12.7K
30NOVOCURE LTDORD SHS0.92%$1M17.4K
31CHINOOK THERAPEUTICS INCCOM0.71%$1M67.8K
32DBCINVESCO DB COMMDY INDX TRCKUNIT0.70%$1M42.4K
33AM6AMICUS THERAPEUTICS INCCOM0.65%$1M108.3K
34RNAGBPAVIDITY BIOSCIENCES INCCOM0.62%$982,00053.2K
35VRTXVERTEX PHARMACEUTICALS INCCOM0.62%$979,0003.8K
36CRNXCRINETICS PHARMACEUTICALS INCOM0.62%$971,00044.2K
37GH RESEARCH PLCORDINARY SHARES0.61%$966,00052.8K
38ARGXARGENX SESPONSORED ADR0.61%$965,0003.1K
39GENERATION BIO COCOM0.61%$964,000131.3K
40DICE THERAPEUTICS INCCOM0.60%$937,00049.0K
41ASCENDIS PHARMA A/SSPONSORED ADR0.58%$918,0007.8K
42VRDNVIRIDIAN THERAPEUTICS INCCOM0.58%$907,00049.1K
43ALNYALNYLAM PHARMACEUTICALS INCCOM0.58%$907,0005.6K
44IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.58%$906,00054.4K
45OPHTEURIVERIC BIO INCCOM0.57%$902,00053.6K
46SRPTSAREPTA THERAPEUTICS INCCOM0.56%$884,00011.3K
471T7TRICIDA INCCOM0.56%$881,000107.2K
48TCE2CELLDEX THERAPEUTICS INC NEWCOM NEW0.56%$877,00025.7K
49KROSKEROS THERAPEUTICS INCCOM0.55%$872,00016.0K
50HORIZON THERAPEUTICS PUB LSHS0.55%$869,0008.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.